Related Experiment Video

Updated: Jul 18, 2026

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

PU.1 and Junb: suppressing the formation of acute myeloid leukemia stem cells

Tim C P Somervaille1, Michael L Cleary

  • 1Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA.

Cancer Cell
|December 13, 2006
PubMed

Insights

Understanding how transcription factors like PU.1 regulate cancer stem cells is key for targeted therapies. Reduced expression of Junb, a downstream effector of PU.1, is linked to acute myeloid leukemia development.

Area of Science:

  • Molecular biology
  • Hematopoiesis
  • Cancer research

Background:

  • PU.1 is a transcription factor crucial for normal myelomonocytic differentiation.
  • Reduced PU.1 activity is implicated in myeloid leukemogenesis.
  • Cancer stem cells play a vital role in tumor development and treatment resistance.

Purpose of the Study:

  • To elucidate the molecular pathways involving PU.1 that suppress cancer stem cell genesis and maintenance.
  • To identify downstream targets of PU.1 that mediate its tumor suppressor functions.
  • To investigate the role of AP-1 transcription factors, Junb and Jun, in PU.1-mediated tumor suppression.

Main Methods:

  • Analysis of gene expression data.
  • Functional assays to assess the role of transcription factors.
  • Studies in relevant cancer models.

Main Results:

  • Junb and Jun, AP-1 transcription factors, are identified as critical downstream effectors of PU.1's tumor suppressor activity.
  • Reduced expression of Junb is a common feature in acute myeloid leukemogenesis.
  • These findings highlight a novel molecular mechanism underlying myeloid leukemia development.

Conclusions:

  • Junb and Jun are key mediators of PU.1's tumor suppressor function in the context of myeloid malignancies.
  • Decreased Junb expression represents a potential biomarker and therapeutic target in acute myeloid leukemia.
  • Targeting these pathways could lead to novel therapeutic strategies for cancer stem cell-driven leukemias.

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation11:40

Retroviral Infection of Murine Embryonic Stem Cell Derived Embryoid Body Cells for Analysis of Hematopoietic Differentiation

Published on: October 20, 2014

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...